Background. Studies to validate a cancer prediction model based on cancer screening markers collected in stored specimens from asymptomatic persons typically require large specimen collection sample sizes. A standard sample size calculation targets a true-positive rate (TPR) of 0.8 with a 2.5% lower bound of 0.7 at a false-positive rate (FPR) of 0.01 with a 5% upper bound of 0.03. If the probability of developing cancer during the study is P = 0.01, the specimen collection sample size based on the standard calculation is 7600. Methods. The strategy to reduce the specimen collection sample size is to decrease both the lower bound of TPR and the upper bound of FPR while keeping a positive lower bound on the anticipated clinical utility. Results. The new sample size calculation targets a TPR of 0.4 with a 2.5% lower bound of 0.10 and an FPR of 0.0 with a 5% upper bound of 0.005. With P = 0.01, the specimen collection sample size based on the new calculation is 1800 instead of 7600. Limitations. The new sample size calculation requires a minimum benefit/cost ratio (number of false positives traded for a true positive). With P = 0.01, the minimum cost-benefit ratio is 5, which is plausible in many studies. Conclusion. In validation studies for cancer screening markers, the strategy can substantially reduce the specimen collection sample size, substantially reducing costs and making some otherwise infeasible studies now feasible.
The first step in the pipeline to develop new cancer screening modalities is the discovery and validation of cancer screening markers to predict the development of cancer in asymptomatic persons. 1, 2 Cancer screening markers can take a variety of forms. For example, investigators are considering the following pancreatic cancer screening markers: genomic markers in the blood, cyst fluid, and pancreatic juice; proteomic markers including CA-19, glycoproteins, and exosomes; and imaging markers involving radiography and radiomics. 3 The discovery phase involves creating a cancer prediction model using markers tested in specimens collected from cases and controls. Usually in the discovery phase, investigators select as cases persons with symptomatic cancer and select as controls persons without symptomatic cancer. This choice of cases and controls facilitates rapidly obtaining results and avoids the concern (with molecular assays) of leaving an insufficient amount of specimen for validation. However, as discussed later, there are drawbacks related to the lack of relevance for the early detection of cancer. The cancer prediction Division of Cancer Prevention, National Cancer Institute, Bethesda, MD (SGB). The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the National Institutes of Health. model should include risk factors, such as age and family history, in addition to the cancer screening markers.
The validation phase involves evaluating the performance of the cancer prediction model derived from the discovery phase in an independent validation sample of asymptomatic persons from whom specimens are collected and stored. The collection of specimens can occur in either 1) a large existing cohort or a clinical trial of asymptomatic people that is typically not designed to investigate the specific cancer or 2) a custom-built smallest practical cohort of asymptomatic persons with target follow-up for a specific cancer. The focus here is on the latter case, such as the Alliance of Pancreatic Cancer Consortia for Early Detection. 3 After specimen collection and follow-up to ascertain cancer incidence, investigators test for the markers in stored specimens from all cases (persons who developed cancer) and random sample of controls (persons who did not develop cancer). For each person with stored specimens tested for the markers, investigators apply the cancer prediction model derived from the discovery phase to the markers and predictors associated with the validation sample. The result is a marker score for each person in the validation sample.
A standard summary of the performance of the cancer prediction model is the receiver operating characteristic (ROC) curve, which plots the true-positive rate (TPR) v. the false-positive rate (FPR) for various cutpoints of the marker score. A marker score larger than a specified cutpoint is called positive; otherwise, it is called negative. TPR, which is also called sensitivity, is the fraction of cases that are positive for the corresponding cutpoint. FPR, which is also called 1 minus specificity, is the fraction of controls that are negative for the corresponding cutpoint.
In this context, validation means finding a combination of FPR and TPR on the ROC curve in the validation sample that indicates a sufficiently promising marker. A major difficulty with validation in a custombuilt cohort of asymptomatic persons is the large sample size needed for specimen collection because the end point of clinical cancer is a rare event in asymptomatic persons. This article develops a strategy to substantially reduce the specimen collection sample size (the total number of stored specimens) for validation.
Specimen Collection and Marker-Testing Sample Sizes
The marker-testing sample size is the number of stored specimens tested for the marker. The specimen collection sample size is related to the marker-testing sample size as follows.
Let x case denote the marker-testing sample size for cases. The expected number of specimens needed to obtain x case marker-testing samples is E case = x case / P, where P is the probability of developing the cancer of interest during the study. The problem with using E case for the specimen collection sample size is that it does account for random variability. A more relevant quantity than E case is N case , the specimen collection sample sized needed to obtain with 95% probability at least x case case specimens for marker testing. N case solves the following equation for the cumulative distribution function (CDF) for a binomial random variable evaluated at x case :
where CDF[Binomial{n, p}, x] = P i = 0
n -i is the probability that a binomial random variable with probability p of a single outcome yields x or fewer outcomes among n events. Computation of N case in equation (1) involves the numerical tabulation of various values for N case .
Let x control denote the marker-testing sample size for controls. The expected number of specimens needed to obtain x control marker-testing samples is E control = x control / (1 -P). Let N control denote the specimen collection sample size needed to obtain with 95% probability at least x control control specimens for marker testing. N control solves the following equation for the CDF for a binomial distribution evaluated at x control :
The specimen collection sample size, N, is the larger of N control and N case . The formulas for E case and E control indicate that for a small P, as with cancer, E case is usually much larger than E control . Correspondingly, N case is usually much larger than N control . Consequently, the specimen collection sample size depends on x case and not on x control , which is important for the sample size reduction strategy.
Standard Specimen Collection Sample Size
For the standard specimen collection sample size, consider the method of Baker et al., 4 which computes the marker-testing sample size by specifying target values . Setting this standard error equal to 0.05, they computed a marker-testing sample size for cases of n = 64, which they rounded up to 70. A slightly different calculation based on half the width of the confidence interval, 1.96 {0.8 (1 -0.8) / n} 1/2 = .80 -.70, gives a marker-testing sample size for cases of 62. Applying equation (1) to the marker-testing sample size for cases of 62, with P = 0.01, yields the standard specimen collection sample size of N STD =7600.
Reduced Specimen Collection Sample Size
The reduced specimen collection sample size is based on the following decision-analytic formulation. Let C denote the cost of a false positive (the anticipated harm from side effects of an incorrect prediction of cancer). Let B denote the benefit of a true positive (the anticipated reduction in cancer mortality from a correct prediction of cancer. Following fundamental work by Peirce, 5 the anticipated clinical utility of the marker score (evaluated at a cutpoint) is the expected benefit of a true positive minus the expected cost of a false positive:
Pepe et al. 6 recommended choosing target false-and true-positive values, FPR target and TPR target , to ensure a positive anticipated clinical utility.
A useful desideratum that incorporates the variability of estimates is a positive lower bound on the anticipated clinical utility. Let TPR lower denote a lower bound for the true-positive rate and FPR upper denote an upper bound for the false-positive rate. The lower bound on the anticipated clinical utility is defined as
A positive lower bound for the anticipated clinical utility (U lower . 0) requires that
Because equation (5) implies B/C . {(1 -P) / P } / (TPR lower / FPR upper ), the target values for FPR upper and TPR lower apply only when the benefit/cost ratio is larger than
(B/C) min is the minimum number of false positives traded for a true positive to ensure a positive lower bound on the anticipated clinical utility. Investigators can choose any pair of FPR upper and TPR lower that satisfies equation (5) to yield a positive lower bound on the anticipated clinical utility. The key insight is that decreasing both FPR upper and TPR lower while satisfying equation (5) can substantially decrease the sample size. Decreasing FPR upper involves estimating FPR more precisely, which corresponds to increasing x control . Decreasing TPR lower involves estimating TPR less precisely, which corresponds to decreasing x case . Because the specimen collection sample size with small P depends on x case and not x control , decreasing x case decreases the specimen collection sample size N.
With this motivation, the new specimen collection sample size calculation specifies target values of Here FPR upper corresponds to the 5% upper bound for the estimated FPR because it is one-sided. As with the standard sample size calculation, TPR lower corresponds to the 2.5% lower bound for the estimated TPR. The exact values for these targets are arbitrary, but values for TPR target and TPR lower that are too small may not be convincing.
Although TPR target = 0.40 may seem small, TPR target = 0.40 at FPR target = 0 yields a positive anticipated clinical utility, U = 0.40 P B, which is 40% of the expected benefit of a correct prediction. Another way to appreciate the desirability of TPR target = 0.40 at FPR target = 0 as a target for classification performance is to compute the corresponding positive and negative predictive values. In this context, the positive predictive value (PPV) is the probability of developing clinical cancer given a positive marker score,
In this context, the negative predictive value (NPV) is the probability of not developing clinical cancer given a negative marker score,
With TPR target = 0.40 and FPR target = 0.0, equations (7) and (8) yield PVP target = 1 for all P and NVP target = 0.98 at P = 0.03. These positive and negative predictive values indicate outstanding prediction.
While not an ideal target, the lower bound of TPR lower = 0.10 is still worthwhile. With FPR target = 0, it yields a positive anticipated clinical utility, U = 0.10 P B, with PPV = 1 for all P and NPV = 0.97 for P = 0.03. With FPR upper = 0.005, it yields a positive anticipated clinical utility by construction, with PPV = 0.38 at P = 0.03 and NPV = 0.97 at P = 0.03.
The marker-testing sample size for controls is the value of x control that solves the following equation corresponding to the 5% upper bound for the estimated FPR,
For FPR upper = 0.002, x control = 1500. For FPR upper = 0.005, x control = 600. The marker-testing samples size is the value for x case that solves the following equation for one-half the width of a 95% confidence interval,
For TPR lower = 0.10, 0.15, 0.20, x case = 11, 15, and 24, respectively. Tables 1 and 2 show (B/C) min , the specimen collection sample, the marker-testing sample sizes, the standard specimen collection sample, and predictive values for various values P and TPR lower , with FPR upper = 0.005 for Table 1 and FPR upper = 0.002 for Table 2 . As shown in Table 1 , for TPR lower = 0.10 with P = 0.01, (B/C) min = 5 and the specimen collection sample size is N = 1800, a substantial reduction from the standard specimen collection sample size of 7600. For the smallest sample sizes, the first step is to consult Table 1 with TPR lower = 0.10 to determine (B/C) min . If the ratio of anticipated benefits to anticipated costs is than larger than (B/C) min , then the corresponding specimen collection sample size in Table 1 applies. Otherwise, it is necessary to consider either a higher risk group (larger P), TPR lower = 0.15 or TPR lower = 0.20, or FPR upper = 0.002. P is the probability of developing cancer during the study. (B/C) min is minimum benefit/cost ratio (number of false positives traded for a true positive) to ensure a positive lower bound for the anticipated clinical utility. x case is the marker-testing sample size for cases. N case is the specimen collection sample size for cases (rounded to the nearest 100). N control is the specimen collection sample size for controls (rounded to the nearest 10). N is the final specimen collection sample size = max(N case , N control ) for the new calculation. N STD is the final specimen collection sample size for the standard calculation that depends only on P in this table. PPV is the positive predictive value for P with TPR low and FPR upper = 0.005. NPV is the negative predictive value for P with TPR low and FPR upper = 0.005.
Example 1: Sample Size with Pancreatic Cancer Screening Markers
Consider using markers and risk factors to predict, for the purpose of screening, pancreatic cancer among highrisk asymptomatic persons age 50 or older with diabetes. For this high-risk group, the probability of developing pancreatic cancer in the next 3 years is P = 0.01. 7 For TPR lower = 0.10 and P = 0.01, Table 1 shows (B/C) min = 5. To determine if the ratio of anticipated benefits to anticipated costs exceeds this minimum, it is necessary to consider the consequences of a positive marker score. A likely scenario is that a positive marker score would be followed by endoscopic ultrasound imaging. A study of endoscopic imaging found the following probabilities of adverse events among possibly overlapping categories: 44% with pancreatitis, 41% with infections, 8% with bleeding, and 1% with perforations. 8 The benefit of early intervention following a positive marker score for pancreatic cancer is unknown, but even a small improvement in survival would be important. Based on these considerations, it is likely that the ratio of anticipated benefits to anticipated costs would be larger than (B/C) min = 5, implying that one would exchange at least 5 false positives for 1 true positive. Based on Table  1 , with P = 0.01 and (B/C) min = 5, the new specimen collection sample size is N = 1800, which is substantially less than the standard specimen collection sample size of N STD = 7600.
Example 2: Sample Size with Ovarian Cancer Screening Markers
Consider using various markers and risk factors to predict, for the purpose of screening, invasive epithelial ovarian or tubal cancer (iEOC) among asymptomatic persons. In a 4-year study involving asymptomatic women ages 50 years or older, the probability of developing iEOC was P = 133/46,237 = 0.003. 9 For TPR lower = 0.10 and P = 0.003, Table 1 shows (B/C) min = 17. To determine if the ratio of anticipated benefits to anticipated costs would likely exceed this minimum, it is necessary to consider the consequences of a P is the probability of developing cancer during the study. (B/C) min is minimum benefit/cost ratio (number of false positives traded for a true positive) to ensure a positive lower bound for the anticipated clinical utility. x case is the marker-testing sample size for cases. N case is the specimen collection sample size for cases (rounded to the nearest 100). N control is the specimen collection sample size for controls (rounded to the nearest 10). N is the final specimen collection sample size = max(N case , N control ) for the new calculation. N STD is the final specimen collection sample size for the standard calculation that depends only on P in this table. PPV is the positive predictive value for P with TPR low and FPR upper = 0.002. NPV is the negative predictive value for P with TPR low and FPR upper = 0.002.
positive marker score. A positive marker score for ovarian cancer would be followed by surgery, usually laparoscopic bilateral salpingo-oophorectomy. 9 For every detection of iEOC, there are approximately 4 surgeries with no iEOC detection and a complication rate of 4.5%. 9 Recent studies found no reduction in ovarian cancer mortality resulting from current ovarian cancer screening. 10 These considerations are consistent with a previous benefit/cost ratio for markers for ovarian cancer screening 6 of B/C = 9, which says that 9 false positives would be traded for 1 true positive. Because B/C is smaller than (B/C) min , it is not worthwhile to implement a trial with TPR lower = 0.10 and P = 0.003 and FPR upper = 0.005. A reasonable strategy is to consider FPR upper = 0.002 in Table 2 , yielding a specimen collection sample size of N = 6000, which is substantially less than the standard specimen collection sample size of N STD = 25,500.
Discussion
The methodology does not require costs and benefits to be measured on the same scale because the focus is on trading false positives (with their associated costs) for true positives (with their associated benefits), as opposed to constructing a combined metric of benefits and costs. By analogy, one can trade apples for oranges without assigning a monetary price to each fruit.
To apply this methodology, it is generally not necessary to specify the ratio of anticipated benefits to anticipated costs. Instead, it is only necessary to perform a simpler task-namely, to determine if the ratio of anticipated benefits to anticipated costs is larger than (B/C) min , the minimum ratio of anticipated benefits to anticipated costs associated with P and TPR lower . For perspective, it is worth noting that standard sample size calculation implicitly requires a positive ratio of anticipated benefits to anticipated costs in specifying acceptable target values for FPR and TPR.
The target values of FPR target = 0.0 and TPR target = 0.40 suggest the following simple data analysis. First, identify the cutpoint at which FPR = 0, which is the largest cutpoint among the controls. Second, compute the lower bound of TPR at this cutpoint and deem the cancer prediction model promising if this TPR lower bound is larger than TPR lower .
The analysis corresponds to selecting FPR and TPR values from the 2-dimensional space of acceptable FPR and TPR values specified by an ROC curve. In fact, a more sophisticated analysis plots the ROC curve and reports the optimal point as the point where the slope of the ROC curve equals (1 -P) / P 3 (C/B). Basic results in decision analysis show that FPR and TPR at this point maximize U for a concave ROC curve. 11, 12 If the upper bound of FPR at the optimal point is less than or equal to FPR upper and the lower bound of TPR at this point is greater than or equal to TPR lower , then the cancer prediction model is deemed as promising. Because FPR is small, the conclusions from the 2 types of analyses should be similar because the slope of the ROC curve at the optimal point is likely close to the ratio of TPR to FPR at the optimal cutpoint.
As mentioned previously, the discovery phase typically uses specimens collected from the persons with symptomatic cancer v. no cancer. The limitation of this usual discovery phase is that it assumes that markers that are good at discriminating between symptomatic cancers and no cancer will also be good at predicting cancer in asymptomatic persons. To avoid this limitation, if it all possible, investigators should implement the ideal discovery phase involving stored specimens from asymptomatic persons who develop cancer v. asymptomatic persons who do not develop cancer. Consequently, the strategy to the reduce specimen collection sample size in the validation phase could also substantially reduce the specimen collection sample size for the ideal discovery phase.
The most important determinant of specimen collection sample is P. If investigators can identify a relevant high-risk group (so P is relatively large), they can obtain smaller sample sizes than otherwise the case. The large reduction in sample size with this new method could allow for prospective testing of markers instead of testing markers in stored specimens, thereby avoiding problems from the degradation of markers in stored samples.
